ATEC and Theradaptive entered into a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platform across global therapeutic applications.
Under the terms of the agreement, ATEC gains exclusive U.S. commercial rights to market and distribute Theradaptive’s OsteoAdapt osteoinductive bone graft for spinal fusion.
Leveraging proprietary AMP2 protein technology, OsteoAdapt is currently being evaluated in clinical trials in spine and dental applications and is subject to FDA premarket approval. The technology has received three FDA Breakthrough Device Designations, underscoring its potential to address unmet medical needs in bone regeneration.
Further, to support the completion of clinical studies and rapid scaling of its technology platform alongside the ATEC partnership, Theradaptive has launched a Series B investment round. This capital will facilitate the advancement of the OASIS Pivotal trial in spinal fusion and the manufacturing scale-up and build-out in support of future commercialization.
ATEC and Theradaptive entered into a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platform across global therapeutic applications.
Under the terms of the agreement, ATEC gains exclusive...
ATEC and Theradaptive entered into a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platform across global therapeutic applications.
Under the terms of the agreement, ATEC gains exclusive U.S. commercial rights to market and distribute Theradaptive’s OsteoAdapt osteoinductive bone graft for spinal fusion.
Leveraging proprietary AMP2 protein technology, OsteoAdapt is currently being evaluated in clinical trials in spine and dental applications and is subject to FDA premarket approval. The technology has received three FDA Breakthrough Device Designations, underscoring its potential to address unmet medical needs in bone regeneration.
Further, to support the completion of clinical studies and rapid scaling of its technology platform alongside the ATEC partnership, Theradaptive has launched a Series B investment round. This capital will facilitate the advancement of the OASIS Pivotal trial in spinal fusion and the manufacturing scale-up and build-out in support of future commercialization.
Copy to clipboard 
